Tofacitinib in the treatment of rheumatoid arthritis

The dynamic development of modern therapies for rheumatoid arthritis (RA) has been observed in recent years. Most of the new drugs are monoclonal antibodies, which are usually directed against specific proinflammatory cytokines. Unfortunately, despite an undoubted progress in the field of biological treatment, it is estimated that about 20–30% of patients with RA do not receive an adequate response to the treatment used. That is why new solut ons are constantly being sought. Janus kinase inhibitors (JAK) are drugs with a different intracellular mechanism of action. These drugs, due to their innovative mechanism of action, give hope for effective treatment of patients who do not respond to therapy with currently available drugs. One of the representatives of JAK inhibitors is tofacitinib. In this manuscript, we provide information on tofacitinib in the context of RA treatment